Zydus Cadila, a global healthcare provider in India, has signed a definitive agreement with Medicure International Inc., a pharmaceutical company based in Manitoba, Canada.
Through the agreement, Zydus can commercialize its 505(b)(2) New Drug Application (NDA) product, pitavastatin magnesium (ZYPITAMAGTM) in the United States, which is used to manage cholesterol levels.
As a part of this agreement, Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAG.
Speaking on the development, Dr. Sharvil Patel, Managing Director, Zydus Cadila said: "The launch of this proprietary drug is in continuation of our commitment to exploring new pathways in pharmaceutical technology with a thrust on enhancing patient care and well-being. In this endeavour, we are happy to partner with Medicure in reaching out to the patient community and helping them access this NDA for desired health outcomes".
"Medicure is pleased to partner with Zydus Cadila and add ZYPITAMAG to its cardiovascular commercial operation. This partnership fits well with Medicure's mission of being a significant cardiovascular pharmaceutical company focused on the U.S. market," commented Medicure's President and CEO, Dr. Albert D. Friesen..
Copyright: North America Procurement Council Inc., PBC